SCHEMBL31417865

SCHEMBL31417865

CCOC(=O)c1ccnc(-c2cccc(O)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 5/20 0.56
MAPT P10636 2/20 0.51
TP53 P04637 2/20 0.51
LMNA P02545 1/20 0.51
THRB P10828 1/20 0.51
KDM1A O60341 1/20 0.51
HDAC1 Q13547 1/20 0.51
JAK2 O60674 1/20 0.50
JAK3 P52333 1/20 0.50
SYK P43405 1/20 0.49
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3900684 0.87 NPC1 (0.56) MAPTTP53NPC1ALDH1A1RAB9A
SCHEMBL4763680 0.86 JMJD6 (0.67) JMJD6MAPTTP53LMNATHRB
SCHEMBL4768424 0.85 JMJD6 (0.54) JMJD6MAPTTP53LMNATHRB
SCHEMBL4763698 0.84 JMJD6 (0.64) JMJD6MAPTTP53LMNATHRB
SCHEMBL30171421 0.83 JMJD6 (0.76) JMJD6
SCHEMBL811785 0.83 JMJD6 (0.76) JMJD6
SCHEMBL6433108 0.82 MAPT (0.62) JMJD6MAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL21311049 0.82 KDM1A (0.48) KDM1AHDAC1NPC1RAB9A
SCHEMBL6888048 0.82 HSD17B1 (0.53) MAPTTP53JAK2JAK3NPC1
SCHEMBL149288 0.81 CA12 (0.67) NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747247-A1 NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF Apogee Pharmaceuticals, Inc. (CA) 2026-05-27 EP disclosed
US-12410137-B2 Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-09-09 US disclosed
US-20250129027-A1 FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2025-04-24 US disclosed
WO-2025015420-A1 NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2025-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129027-A1 FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF FAAH, FAAH2, MGLL JMJD6 478/4885MAPT 4264/4885TP53 4861/4885
US-12410137-B2 Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof FAAH, FAAH2, MGLL JMJD6 478/4885MAPT 4264/4885TP53 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.